以下部分引用 AI 总结，现阶段 AI 仍然有幻觉。请以内容的原文为准。

数据新鲜度群聊 07-14 ✓卖方 07-14 ✓Wrap 断档15天 ✕News 07-15 ✓X 断档12天 ✕页面生成 07-15

VKTX

32 atoms · 跨 5 天 · 首见 2026-04-29 · 最近 2026-06-24

三色: 🟦 fact 27 · 🟥 take 5 · stance ▲14/▼0/◆1

叙事状态: 🍂 fading (退潮) · 💤 沉寂 · 策展近14d 0 atom

状态只算低频策展源 (群/卖方); X firehose 仅作背景音量

来源: X 32

时态: fresh:32

标签: 好数字:17 · 好信源:13 · 好观点:5 · 好思考:2

🟨 AI 综合 · junior analyst 概览

展开 AI 综合 (灰色 · 非市场结论 · 点击数字溯源到原 atom)

model: deepseek-chat · 2026-07-12 · 默认折叠

Viking Therapeutics 被分析师视为差异化的肥胖症领域参与者，其肥胖症药物 VK2735 具有重磅潜力 ¹ ¹. 公司计划在 2026 年下半年启动口服 VK2735 的三期临床试验 ¹. 临床前数据显示，该药物可在 72 小时内使动物体重降低高达 8% ¹. Lake Street 首次覆盖并给予买入评级，目标价 89 美元 ¹ ¹. Truist Securities 也重申买入并将目标价从 75 美元上调至 83 美元 ¹ ¹. 基于当前价格 31.66 美元，预计上涨空间达 169%-181% ¹ ¹. 管理层的 DACRA 管线有望与 GLP-1 药物联用或单独使用，以改善减重效果 ¹. 虽然公司目前每股亏损 1.37 美元 ¹，但分析师预计其 2040 年风险调整后销售额可达约 30 亿美元 ¹.

🟦 客观事实 (facts) (27)

<a id="atom-dae2fda8d67819d0"></a>🟦 2026-06-24 X·@AIStockSavvy · preclinical weight reduction · 产品发布
Preclinical data showed up to 8% body-weight reduction within 72 hours in animal studies.
tags: 好数字·好信源 · → daily
value: qty=8% · date=within 72 hours
<a id="atom-fb746b7c674b10fd"></a>🟦 2026-05-28 X·@AIStockSavvy · 获得分析师首次覆盖评级 · 评级目标价
Lake Street initiates Viking Therapeutics with a Buy rating, sets PT at $89
tags: 好数字·好信源 · → daily
[图: Lake Street对Viking Therapeutics (VKTX) 首次覆盖的分析师评级与目标价图表 — 目标价: $89.00; 当前价格: $31.66; 预计涨幅: +181.11%; 2040年风险调整销售额预测: ~$3B]
📷 原图
<a id="atom-c3f39aed9bdcf0e8"></a>🟦 2026-05-28 X·@AIStockSavvy · Lake Street price target · 评级目标价
PT at $89
tags: 好数字·好信源 · → daily
value: qty=$89.00
[图: Lake Street对Viking Therapeutics (VKTX) 启动覆盖的分析师评级和目标价信息图 — 目标价 (Price Target): $89.00; 预测涨幅 (Projected Upside): +181.11%; 当前价格 (Current Price): $31.66]
📷 原图
<a id="atom-72afbdb1ed826b49"></a>🟦 2026-06-24 X·@AIStockSavvy · Phase 3 trial plan for oral VK2735 · 产品发布
Company plans to launch a Phase 3 trial of oral VK2735 later in 2026.
tags: 好信源·好思考 · → daily
value: date=later in 2026
<a id="atom-18201ca7688b0ad9"></a>🟦 2026-06-24 X·@AIStockSavvy · CEO statement on DACRA potential · 管理层表态/技术路线
"Therapies that target amylin and calcitonin receptors may potentially be used alone or in combination with GLP-1 or dual GLP-1/GIP agonists to improve the induction of weight loss as well as for longer-term weight management." — Brian Lian.
tags: 好信源·好观点 · → daily
<a id="atom-d53ee8e68003ad0d"></a>🟦 2026-04-29 X·@AIStockSavvy · EPS · 盈利能力
实际每股收益(Actual EPS): -1.37
tags: 好数字 · → daily
value: qty=-1.37 · date=Q1 2026
[图: Viking Therapeutics Inc. 2026年第一季度每股收益(EPS)与营收财报数据图 — 实际每股收益(Actual EPS): -1.37; 预期每股收益(Expected EPS): -0.91; 每股收益同比(EPS YoY): -234.15%; 每股收益未达预期比例(EPS Miss): -50.55%]
📷 原图
<a id="atom-364e53bd8af46dd4"></a>🟦 2026-05-28 X·@AIStockSavvy · 当前股价与预计涨幅 · 价格动态
目标价: $89.00; 当前价格: $31.66; 预计涨幅: +181.11%
tags: 好数字 · → daily
value: qty=+181.11% · date=当前
[图: Lake Street对Viking Therapeutics (VKTX) 首次覆盖的分析师评级与目标价图表 — 目标价: $89.00; 当前价格: $31.66; 预计涨幅: +181.11%; 2040年风险调整销售额预测: ~$3B]
📷 原图
<a id="atom-a27fdd0e04d01c0a"></a>🟦 2026-05-27 X·@AIStockSavvy · 前目标价 · 评级目标价
From: $75.00
tags: 好数字 · → daily
value: qty=$75.00 · date=之前
[图: Truist Securities 对 Viking Therapeutics (VKTX) 的分析师评级、目标价上调及投资要点分析图 — 新目标价 (New Target): $83.00; 当前价格 (Current Price): $30.80; 预计上涨空间 (Projected Upside): +169.48%; 前目标价 (From):
📷 原图
<a id="atom-84fce130af03aec5"></a>🟦 2026-05-27 X·@AIStockSavvy · 13周疗效 · 产品发布
Efficacy in 13 weeks: 14.7%
tags: 好数字 · → daily
value: qty=14.7% · date=13周
[图: Truist Securities 对 Viking Therapeutics (VKTX) 的分析师评级、目标价上调及投资要点分析图 — 新目标价 (New Target): $83.00; 当前价格 (Current Price): $30.80; 预计上涨空间 (Projected Upside): +169.48%; 前目标价 (From):
📷 原图
<a id="atom-daba36463cc518d3"></a>🟦 2026-06-24 X·@AIStockSavvy · Phase 1 trial initiation · 产品发布
Viking Therapeutics initiated a Phase 1 trial of weight-loss candidate VK3019.
tags: 好信源 · → daily
<a id="atom-82767926dec38abb"></a>🟦 2026-06-24 X·@AIStockSavvy · VK3019 mechanism · 技术路线
VK3019 is a dual amylin and calcitonin receptor agonist (DACRA).
tags: 好信源 · → daily
<a id="atom-560ff4bb546246ae"></a>🟦 2026-06-24 X·@AIStockSavvy · FDA IND clearance · 监管政策
FDA clearance of VK3019's Investigational New Drug application.
tags: 好信源 · → daily
<a id="atom-461d5eea775da367"></a>🟦 2026-06-24 X·@AIStockSavvy · Phase 1 study design · 产品发布
Study will evaluate safety, tolerability, and pharmacokinetics in adults with BMI ≥ 30.
tags: 好信源 · → daily
<a id="atom-ddaa89df5babc76a"></a>🟦 2026-06-24 X·@AIStockSavvy · Phase 3 VANQUISH trial status · 产品发布
Viking is also conducting Phase 3 VANQUISH trials for obesity drug VK2735.
tags: 好信源 · → daily
<a id="atom-b18fc26d83e9e051"></a>🟦 2026-06-24 X·@AIStockSavvy · CEO statement on VK3019 · 管理层表态/产品发布
"The initiation of VK3019's Phase 1 study marks an important expansion of our portfolio of novel therapies designed to optimize the weight loss journey for patients and their physicians." — Brian Lian, Ph.D., CEO of Viking Therapeutics.
tags: 好信源 · → daily
<a id="atom-e2d7b634c2f94fac"></a>🟦 2026-06-24 X·@AIStockSavvy · CEO statement on treatment options · 管理层表态
"Broadening the potential treatment options is crucial to meeting the diverse needs of individuals seeking safe and sustainable weight loss." — Brian Lian.
tags: 好信源 · → daily
<a id="atom-de7224d806ee925f"></a>🟦 2026-05-28 X·@AIStockSavvy · current price · 价格动态
Current Price: $31.66
tags: 好数字 · → daily
value: qty=$31.66
[图: Lake Street对Viking Therapeutics (VKTX) 启动覆盖的分析师评级和目标价信息图 — 目标价 (Price Target): $89.00; 预测涨幅 (Projected Upside): +181.11%; 当前价格 (Current Price): $31.66]
📷 原图
<a id="atom-aa60495dcd54f3dd"></a>🟦 2026-05-28 X·@AIStockSavvy · projected upside from current price to PT · 评级目标价
Projected Upside: +181.11%
tags: 好数字 · → daily
value: qty=+181.11%
[图: Lake Street对Viking Therapeutics (VKTX) 启动覆盖的分析师评级和目标价信息图 — 目标价 (Price Target): $89.00; 预测涨幅 (Projected Upside): +181.11%; 当前价格 (Current Price): $31.66]
📷 原图
<a id="atom-7788cb53e5c5707d"></a>🟦 2026-05-27 X·@AIStockSavvy · 当前价格 · 价格动态
Current Price: $30.80
tags: 好数字 · → daily
value: qty=$30.80 · date=当前
[图: Truist Securities 对 Viking Therapeutics (VKTX) 的分析师评级、目标价上调及投资要点分析图 — 新目标价 (New Target): $83.00; 当前价格 (Current Price): $30.80; 预计上涨空间 (Projected Upside): +169.48%; 前目标价 (From):
📷 原图
<a id="atom-ffbb9ce29d7a4adf"></a>🟦 2026-05-12 X·@AIStockSavvy · Phase 2 oral VK2735 weight loss · 临床数据
Oral VK2735 achieved up to 12.2% weight loss in 13 weeks.
tags: 好数字 · → daily
value: qty=12.2% · date=13 weeks
<a id="atom-950b7f704b9d488d"></a>🟦 2026-05-12 X·@AIStockSavvy · Phase 2 placebo weight loss · 临床数据
Placebo group recorded 1.3% average weight reduction.
tags: 好数字 · → daily
value: qty=1.3%
<a id="atom-8bd8a9199be12bcc"></a>🟦 2026-05-12 X·@AIStockSavvy · Phase 2 trial enrollment · 临床数据
Trial enrolled 280 adults with obesity or overweight conditions.
tags: 好数字 · → daily
value: qty=280
<a id="atom-7476043192aa1e17"></a>🟦 2026-05-12 X·@AIStockSavvy · Phase 2 participants achieving 5% weight loss · 临床数据
Up to 97% of participants achieved at least 5% weight loss.
tags: 好数字 · → daily
value: qty=97%
<a id="atom-242fb284a3716a4d"></a>🟦 2026-05-28 X·@AIStockSavvy · Lake Street analyst rating · 评级目标价
$VKTX | Lake Street initiates Coverage on Viking Therapeutic with Buy, initiates PT at $89
tags: 好信源 · → daily
value: qty=Buy
[图: Lake Street对Viking Therapeutics (VKTX) 启动覆盖的分析师评级和目标价信息图 — 目标价 (Price Target): $89.00; 预测涨幅 (Projected Upside): +181.11%; 当前价格 (Current Price): $31.66]
📷 原图
<a id="atom-4c2041aa1a1f9de6"></a>🟦 2026-05-12 X·@AIStockSavvy · drug mechanism · 技术路线
Treatment targets both GLP-1 and GIP receptors.
tags: 好思考 · → daily
<a id="atom-b7c491c1b5ee483d"></a>🟦 2026-05-12 X·@AIStockSavvy · weight loss onset and trajectory · 临床数据
Weight loss began by week 1 and continued without plateauing.
tags: 好观点 · → daily
<a id="atom-8c720f8635ace589"></a>🟦 2026-05-12 X·@AIStockSavvy · Phase 3 plans for oral VK2735 · 研发进展
Viking plans to launch Phase 3 trials for oral VK2735 this year.
tags: 好观点 · → daily

🟥 多头 takes (bullish) (5)

<a id="atom-abc61236cb144c60"></a>🟥 2026-05-28 X·@AIStockSavvy · 2040年风险调整销售额预测 · 营收预测/TAM
2040年风险调整销售额预测: ~$3B
tags: 好数字 · → daily
value: qty=~$3B · date=2040
[图: Lake Street对Viking Therapeutics (VKTX) 首次覆盖的分析师评级与目标价图表 — 目标价: $89.00; 当前价格: $31.66; 预计涨幅: +181.11%; 2040年风险调整销售额预测: ~$3B]
📷 原图
<a id="atom-d8b17df421adb89d"></a>🟥 2026-05-27 X·@AIStockSavvy · 目标价 · 评级目标价
Truist Securities reiterates Buy on Viking Therapeutics, raises PT to $83 from $75
tags: 好数字 · → daily
value: qty=$83 · date=当前
[图: Truist Securities 对 Viking Therapeutics (VKTX) 的分析师评级、目标价上调及投资要点分析图 — 新目标价 (New Target): $83.00; 当前价格 (Current Price): $30.80; 预计上涨空间 (Projected Upside): +169.48%; 前目标价 (From):
📷 原图
<a id="atom-531a14c866be36c7"></a>🟥 2026-05-27 X·@AIStockSavvy · 预计上涨空间 · 评级目标价
Projected Upside: +169.48%
tags: 好数字 · → daily
value: qty=+169.48% · date=当前
[图: Truist Securities 对 Viking Therapeutics (VKTX) 的分析师评级、目标价上调及投资要点分析图 — 新目标价 (New Target): $83.00; 当前价格 (Current Price): $30.80; 预计上涨空间 (Projected Upside): +169.48%; 前目标价 (From):
📷 原图
<a id="atom-54881680f87efb39"></a>🟥 2026-05-28 X·@AIStockSavvy · 分析师目标价 · 产品发布
Analyst initiates on Viking with a Buy rating, citing blockbuster potential for obesity drug VK2735 and upside from its broader metabolic pipeline.
tags: 好观点 · → daily
value: qty=$89 · date=当前
[图: Lake Street对Viking Therapeutics (VKTX) 首次覆盖的分析师评级与目标价图表 — 目标价: $89.00; 当前价格: $31.66; 预计涨幅: +181.11%; 2040年风险调整销售额预测: ~$3B]
📷 原图
<a id="atom-25e8a5ac947afe10"></a>🟥 2026-05-27 X·@AIStockSavvy · 分析师观点 · 竞争格局
Analyst sees VKTX as a differentiated obesity player, citing fast efficacy, flexible formulations for adherence, and a diversified metabolics pipeline
tags: 好观点 · → daily
[图: Truist Securities 对 Viking Therapeutics (VKTX) 的分析师评级、目标价上调及投资要点分析图 — 新目标价 (New Target): $83.00; 当前价格 (Current Price): $30.80; 预计上涨空间 (Projected Upside): +169.48%; 前目标价 (From):
📷 原图

⏱ 时间轴 (近 20)

🟦 2026-06-24 · fact · Phase 1 trial initiation · → daily
🟦 2026-06-24 · fact · VK3019 mechanism · → daily
🟦 2026-06-24 · fact · FDA IND clearance · → daily
🟦 2026-06-24 · fact · Phase 1 study design · → daily
🟦 2026-06-24 · fact · preclinical weight reduction · → daily
🟦 2026-06-24 · fact · Phase 3 VANQUISH trial status · → daily
🟦 2026-06-24 · fact · Phase 3 trial plan for oral VK2735 · → daily
🟦 2026-06-24 · fact · CEO statement on VK3019 · → daily
🟦 2026-06-24 · fact · CEO statement on DACRA potential · → daily
🟦 2026-06-24 · fact · CEO statement on treatment options · → daily
🟦 2026-05-28 · fact · Lake Street analyst rating · → daily
🟦 2026-05-28 · fact · Lake Street price target · → daily
🟦 2026-05-28 · fact · current price · → daily
🟦 2026-05-28 · fact · projected upside from current price to PT · → daily
🟦 2026-05-28 · fact · 获得分析师首次覆盖评级 · → daily
🟥 2026-05-28 · narrative · 分析师目标价 · → daily
🟦 2026-05-28 · fact · 当前股价与预计涨幅 · → daily
🟥 2026-05-28 · forecast · 2040年风险调整销售额预测 · → daily
🟥 2026-05-27 · forecast · 目标价 · → daily
🟥 2026-05-27 · narrative · 分析师观点 · → daily

← 实体目录 · 系统日志